Christopher Lambert, MD
Cardiovascular Disease · Scottsbluff, NENPI 1104846070
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 33.4% of the total. Reporting peaked in 2019 at $358 and has fallen 51.8% since, to $173 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NE, where the typical reported total is $1,663.
Across 124 payments — averaging $14.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$604
- Novartis$259
- Merck$135
- Otsuka America Pharmaceutical, Inc.$125
- Boehringer Ingelheim$104
- Johnson & Johnson$102
- plus $479 from 10 others
What the payments were for
- Food & beverage$1,807100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 67 | $604 |
| Novartis | 12 | $259 |
| Merck | 9 | $135 |
| Otsuka America Pharmaceutical, Inc. | 4 | $125 |
| Boehringer Ingelheim | 7 | $104 |
| Johnson & Johnson | 5 | $102 |
| Itamar Medical Inc | 2 | $100 |
| Scpharmaceuticals Inc. | 2 | $84 |
| Amarin Pharma, Inc. | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $43 |
| Janssen Scientific Affairs, LLC | 1 | $43 |
| Pfizer | 3 | $40 |
| Amgen | 2 | $39 |
| Lantheus Medical Imaging, Inc. | 2 | $37 |
| AstraZeneca | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
How this compares
$1,807 in reported general payments places this provider in the 50th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 529 | $486,597 |
| XareltoRivaroxaban | 69 | $50,188 |
| JardianceEmpagliflozin | 43 | $33,938 |
| EntrestoSacubitril/Valsartan | 22 | $31,907 |
| Praluent PenAlirocumab | 11 | $11,551 |
| BrilintaTicagrelor | 14 | $11,446 |
| Telmisartan | 491 | $9,590 |
| Repatha SureclickEvolocumab | 16 | $8,685 |
| Metoprolol Succinate | 544 | $7,776 |
| Atorvastatin Calcium | 826 | $7,094 |
| Amlodipine Besylate | 603 | $3,482 |
| Carvedilol | 546 | $3,141 |
| Valsartan | 127 | $3,113 |
| Nebivolol Hcl | 32 | $2,345 |
| Metoprolol Tartrate | 333 | $1,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $40 | $486,597529 claims |
| Johnson & JohnsonXarelto | $102 | $50,18869 claims |
| Boehringer IngelheimJardiance | $104 | $33,93843 claims |
| NovartisEntresto | $259 | $31,90722 claims |
| AstraZenecaBrilinta | $16 | $11,44614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Scottsbluff
- Ronald ZoltyOmaha$945K
- Robert PercellLincoln$918K
- Steven KruegerLincoln$388K
- Jeffrey CarstensOmaha$124K
- Keith MillerLincoln$86K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Wynn HunterLincoln$46K
- Edward OlearyOmaha$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.